Rx makers should work to reframe pricing debate

October 12, 2015 by Jeffrey Woldt and Chain Drug Review 2016 presidential race, Affordable Care Act, Bernie Sanders, cost of prescription drugs, Daraprim, Harvoni, Hillary Clinton, Jeffrey Woldt, pharmaceutical prices, Sovaldi, Viekira Pak 2015, Issue 10-12-2015, Issues, Opinion

The 2016 presidential race is already well under way. Despite thousands of speeches, interviews and, on the Republican side, two debates, there is a lot about the candidates’ thinking that needs to be clarified. One thing, however, is certain —  health care will be a prominent issue as the process of choosing Barack Obama’s successor